Results 131 to 140 of about 4,355,944 (375)

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Practical program repair via bytecode mutation [PDF]

, 2019
Ali Ghanbari, Samuel Benton, Lingming Zhang   +2 more
openalex   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

The hereditary mutation G51D unlocks a distinct fibril strain transmissible to wild-type α-synuclein [PDF]

, 2021
Yunpeng Sun, Houfang Long, Wencheng Xia, Kun Wang, Xia Zhang, Bo Sun, Qin Cao, Yaoyang Zhang, Bin Dai, Dan Li, Cong Liu   +10 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations [PDF]

, 2013
Tomoaki Kinno, K. Tsuta, Kouya Shiraishi, Takuro Mizukami, Mikiko Suzuki, Akihiko Yoshida, Kenji Suzuki, Hisao Asamura, Koh Furuta, Takashi Kohno, Ryoji Kushima   +10 more
openalex   +1 more source

Assessment on cytotoxic and mutagenic potency of Gamma rays and EMS in Vigna mungo L. Hepper

Biotecnología Vegetal, 2019
To determine the mutagen agent potency and deduce an optimum dose, cytological analysis for induced chromosomal aberrations is considered as an accurate index in mutation breeding.
Sonu Goyal, Mohammad Rafiq Wani, Rafiul Amin Laskar, Aamir Raina, Samiullah Khan   +4 more
doaj  

The gene encoding flavonol synthase contributes to lesion mimic in wheat

Crop Journal
Lesion mimic often exhibits leaf disease-like symptoms even in the absence of pathogen infection, and is characterized by a hypersensitive-response (HR) that closely linked to plant disease resistance.
Tingting Dong, Hongchun Xiong, Huijun Guo, Yongdun Xie, Linshu Zhao, Jiayu Gu, Huiyuan Li, Shirong Zhao, Yuping Ding, Xiyun Song, Luxiang Liu   +10 more
doaj   +1 more source

Nivolumab in previously untreated melanoma without BRAF mutation.

New England Journal of Medicine, 2015
C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J. Hassel, P. Rutkowski, C. McNeil, E. Kalinka‐Warzocha, K. Savage, M. Hernberg, C. Lebbé, J. Charles, C. Mihalcioiu, V. Chiarion-Sileni, C. Mauch, F. Cognetti, A. Arance, H. Schmidt, D. Schadendorf, H. Gogas, L. Lundgren-Eriksson, C. Horak, B. Sharkey, I. Waxman, V. Atkinson, P. Ascierto   +27 more
semanticscholar   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source